Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B

Prof Manuela Schmidinger and Dena Battle
Safety and quality of life assessment, how do they impact patient decision? KCCure survey – part B ( Prof Manuela Schmidinger and Dena Battle )
22 May 2024

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa  - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
21 May 2024

CAR-T, bispecifics or ADCs in late-stage RRMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy
CAR-T, bispecifics or ADCs in late-stage RRMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
8 May 2024

Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM

Dr Elena Zamagni - University of Bologna, Bologna, Italy
Complementing clinical trials: Investigating the value of real world evidence with insights from TE NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
8 May 2024

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI

Dr Elena Zamagni - University of Bologna, Bologna, Italy
Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )
8 May 2024

Treatment of multiple myeloma in Turkey

Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey
Treatment of multiple myeloma in Turkey ( Dr Güldane Cengiz Seval - Ankara University, Ankara, Turkey )
1 May 2024

Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Melflufen and dexamethasone versus pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
30 Apr 2024

Grand Rounds: Improving quality of patient-centred care

Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado
Grand Rounds: Improving quality of patient-centred care ( Dr Didier Verhoeven, Prof Nirmala Bhoo Pathy and Dr Luzia Travado )
30 Apr 2024

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel
Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer ( Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel )
29 Apr 2024

Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer

Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece
Avelumab plus platinum-based chemotherapy may show some efficacy in patients with extensive-stage small cell lung cancer ( Dr Giannis Mountzios - Henry Dunant Hospital Center, Athens, Greece )
26 Apr 2024

A combined PET-MRI scan could improve treatment for patients with early breast cancer

Dr Rosa Di Micco - San Raffaele Hospital, Milan, Italy
A combined PET-MRI scan could improve treatment for patients with early breast cancer ( Dr Rosa Di Micco - San Raffaele Hospital, Milan, Italy )
26 Apr 2024

EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer

Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium)
EBCC 2024: Addressing inequalities across Europe in access to innovation for patients with metastatic breast cancer ( Dr Fiorita Poulakaki (Athens Medical Centre Hospital, Athens, Greece) and Dr Michail Ignatiadis (Institut Jules Bordet, Brussels, Belgium) )
25 Apr 2024